Gilead Sciences is touting a phase 3 win for its drug-antibody conjugate Trodelvy (sacituzumab govitecan-hziy), saying it significantly improved progression-free survival in women with metastatic, treatment-resistant breast cancer.
Source: Drug Industry Daily